Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes.
The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.
Gonzalez-Quesada
Carlos
C
Section of Cardiovascular Sciences, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Frangogiannis
Nikolaos G
NG
D054058:Acute Coronary Syndrome / Q000097:blood*; D015415:Biomarkers / Q000097:blood*; D018932:Chemokine CCL2 / Q000097:blood*; D006801:Humans
D015415:Biomarkers; C111835:CCL2 protein, human; D018932:Chemokine CCL2